About
Technology
Issues
FAQ
Links
Official Page
Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: Final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902).
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.